Literature DB >> 29384521

Prostate cancer: PROMs suggest a festival of benefits in LATITUDE.

Annette Fenner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29384521     DOI： 10.1038/nrurol.2018.12

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

Authors:  Kim N Chi; Andrew Protheroe; Alfredo Rodríguez-Antolín; Gaetano Facchini; Henrik Suttman; Nobuaki Matsubara; Zhangqun Ye; Bhumsuk Keam; Ronaldo Damião; Tracy Li; Kelly McQuarrie; Bin Jia; Peter De Porre; Jason Martin; Mary B Todd; Karim Fizazi
Journal:  Lancet Oncol       Date:  2018-01-08       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.